coefficient of PTH (b=0.199 to b=0.213, 7.0%) and was not a significant predictor of CIMT (p=0.209), suggesting that the relationship was not mediated by vitamin D. Conclusion In this high-risk older cohort, high serum PTH levels are associated with increased CIMT independent of traditional atherosclerotic risk factors.
Introduction Vitamin D may be an important biomarker of cardiovascular disease. Older patients are at particularly high risk of adverse outcomes following non-ST elevation acute coronary syndrome (NSTEACS). Low vitamin D has been previously linked to endothelial dysfunction and vascular stiffness. Therefore, the higher incidence of low vitamin D in older adults may play a plausible mechanistic role in predisposing this cohort to higher risk. The association between vitamin D, endothelial function, vascular stiffness and early outcomes after invasive management of NSTEACS in older patients was evaluated. Methods We evaluated 294 consecutive older patients (aged 65 years) with NSTEACS managed by an invasive strategy. Serum total vitamin D was measured pre-procedure by electrochemiluminescent immunoassay. Endothelial function was determined using peripheral arterial tonometry and vascular stiffness with carotid-femoral pulse wave velocity (PWV), both within 24 hours post-procedure. Major Adverse Cardiovascular Events (MACE) were defined as 30 day composite of all-cause mortality, acute coronary syndrome, unplanned repeat Background Novel pathways utilise low concentrations of cardiac troponin and a normal ECG to risk stratify patients with suspected acute coronary syndrome. However, clinical risk scores incorporating additional cardiovascular risk factors or physiological parameters are commonly used in practice. Whether such clinical risk scores are safer than novel pathways is uncertain. Methods Patients with suspected acute coronary syndrome (n=1,139) underwent high-sensitivity cardiac troponin I testing at presentation, 3 and 6 or 12 hours. We applied the High-STEACS pathway, which rules out myocardial infarction in those without ischaemia on the ECG if troponin concentrations are <5 ng/L at presentation and symptom duration is 2 hours. Early presenters and those 5 ng/L are ruled out if absolute change is <3 ng/L at 3 hours and they remain 99th centile. We compared the HighSTEACS pathway with the HEART score (low risk 3), or a TIMI score of 0 with a normal ECG. We compared the negative predictive value (NPV) and efficacy of each approach for a primary outcome of index type 1 myocardial infarction, or type 1 myocardial infarction or cardiac death at 30 days. Results The primary outcome occurred in 15.5% (177/1,139). The HighSTEACS pathway ruled out 61.9% (705/1,139) of patients by three hours, with a NPV of 99.6% [95%CI 99.1%-99.9%]. The NPV of both the HEART and the TIMI score was similar ( Figure 1A) , however, they identified a significantly lower proportion of patients as eligible for discharge (HEART 18% (205/1,139), TIMI 26.3% (299/1,139); Figure 1B ). Conclusions The HighSTEACS pathway identifies patients at very low risk of index myocardial infarction, or myocardial infarction or cardiac death at 30 days, and rules out acute coronary syndrome in over half of patients presenting to the Emergency Department. Whilst the HEART and the TIMI
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